JP2024503727A5 - - Google Patents
Info
- Publication number
- JP2024503727A5 JP2024503727A5 JP2023543284A JP2023543284A JP2024503727A5 JP 2024503727 A5 JP2024503727 A5 JP 2024503727A5 JP 2023543284 A JP2023543284 A JP 2023543284A JP 2023543284 A JP2023543284 A JP 2023543284A JP 2024503727 A5 JP2024503727 A5 JP 2024503727A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- roflumilast
- pharmaceutical composition
- equivalent amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163199728P | 2021-01-20 | 2021-01-20 | |
| US63/199,728 | 2021-01-20 | ||
| PCT/US2022/013197 WO2022159632A1 (en) | 2021-01-20 | 2022-01-20 | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503727A JP2024503727A (ja) | 2024-01-26 |
| JP2024503727A5 true JP2024503727A5 (cg-RX-API-DMAC7.html) | 2025-01-22 |
Family
ID=80447922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543284A Pending JP2024503727A (ja) | 2021-01-20 | 2022-01-20 | うつ病及び関連する状態の治療のための併用薬物戦略としてのcAMPシグナル伝達の強化 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220226302A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4281065A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024503727A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022159632A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4281065A1 (en) * | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
| CN122421966A (zh) * | 2023-10-12 | 2026-07-17 | 傲拓神经科学公司 | 用替伐普兰治疗神经精神病症 |
| US20250144092A1 (en) * | 2023-11-07 | 2025-05-08 | Alto Neuroscience, Inc. | Treatment of psychiatric or neurological disorders in patients with prominent anhedonia using irdabisant as a monotherapy or in combination with an antipsychotic agent |
| AU2024413931A1 (en) * | 2023-12-28 | 2026-07-02 | Alto Neuroscience, Inc. | Compositions and methods for treating anhedonia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9407182A (pt) | 1993-08-06 | 1996-09-17 | Connaught Lab | Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado |
| EP1811992A2 (en) * | 2004-10-28 | 2007-08-01 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
| WO2007047978A2 (en) * | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| FR2915098B1 (fr) | 2007-04-19 | 2009-06-05 | Sanofi Aventis Sa | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere |
| JP2014525927A (ja) * | 2011-08-18 | 2014-10-02 | シャイアー アーゲー | 治療法に使用される5−ht4受容体アゴニスト及びpde4阻害剤の組合せ |
| WO2014159776A1 (en) * | 2013-03-14 | 2014-10-02 | Cephalon, Inc. | Solid state forms of 6-[4-[3-(r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride |
| CA2921308A1 (en) * | 2013-08-16 | 2015-02-19 | Universiteit Maastricht | Treatment of cognitive impairment with pde4 inhibitor |
| JOP20190219A1 (ar) * | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
| US10517841B1 (en) * | 2018-06-14 | 2019-12-31 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| JP7821116B2 (ja) * | 2020-04-07 | 2026-02-26 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法 |
| EP4281065A1 (en) * | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
-
2022
- 2022-01-20 EP EP22704089.6A patent/EP4281065A1/en active Pending
- 2022-01-20 US US17/648,539 patent/US20220226302A1/en not_active Abandoned
- 2022-01-20 JP JP2023543284A patent/JP2024503727A/ja active Pending
- 2022-01-20 WO PCT/US2022/013197 patent/WO2022159632A1/en not_active Ceased
- 2022-12-09 US US18/063,907 patent/US20230117508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Staunstrup et al. | Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain | |
| Langemark et al. | Sulpiride and paroxetine in the treatment of chronic tension‐type headache. An explanatory double‐blind trial | |
| TW200808696A (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| TWI826380B (zh) | Nk-1 拮抗劑組合物及用於治療抑鬱症之方法 | |
| US20180092916A1 (en) | Methods of treating disease-induced ataxia and non-ataxic imbalance | |
| JP2023535744A (ja) | 片頭痛の治療 | |
| WO2013063263A1 (en) | Pharmaceutical compositions for treating pain | |
| JP2022116304A (ja) | 血液がんの治療のためのPPARγアゴニスト | |
| JP2005505539A (ja) | パーキンソン病の治療のためのcb1受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 | |
| WO2010030755A1 (en) | Methods of using sustained release aminopyridine compositions | |
| Smith-Apeldoorn et al. | Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study | |
| EP2464229A1 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| CN114727989A (zh) | Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合 | |
| JP2023531930A5 (cg-RX-API-DMAC7.html) | ||
| JP2014534229A5 (cg-RX-API-DMAC7.html) | ||
| JP2013536206A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2018221728A1 (ja) | アルツハイマー型認知症予防または治療剤 | |
| JP2024544500A5 (cg-RX-API-DMAC7.html) | ||
| TWI457123B (zh) | 4-{3-[順式-六氫環戊并[c]吡咯-2(1h)-基]丙氧基}苯甲醯胺與nmda受體拮抗劑之新結合及包含彼等之醫藥組合物 | |
| JP2005531594A5 (ja) | 慢性痛の治療用トリプルモノアミン再取り込み阻害剤 | |
| Graham et al. | Safety of tiotropium Respimat® in black or African-American patients with symptomatic asthma | |
| JP2022506019A (ja) | 高用量の放出調節フペルジン製剤の使用 | |
| CN110461330A (zh) | 用于治疗亨廷顿氏病的PPARγ激动剂 | |
| JP2024518426A5 (cg-RX-API-DMAC7.html) | ||
| JP2002521431A (ja) | モクロベマイドの使用方法および組成物 |